Cheshire,UK (PRWEB UK) 1 April 2012

Immunisation against mumps from a single vaccine will be available from June 2012 at the Childrens Immunisation Centre. There has been a shortage of the single mumps vaccine since 2009 when the US company Merck & Co began to halt manufacture of single measles, mumps and rubella vaccines while launching their cervical cancer vaccine Gardasil.

The British manufactured mumps vaccine that will be available through the Childrens Immunisation Centre from June is Jeryl-Lynn strain. The new Medi-Mumps? vaccine is cultured on animal kidney cells; the vaccine that is to become available in the UK this summer does not grow the mumps virus strain on chick embryo fibroblast (CEF) cell cultures so the vaccine is suitable for the many babies that are egg allergy sufferers. The vaccine has been proven clinically in Europe.

The availability of the single mumps vaccine will come as a huge relief to parents of children who have yet to be immunised against the virus due to the lack of supply of the vaccine in the UK over the last three years.

While parents concerned about the safety of the MMR vaccine have been able to get their children immunised against measles and rubella through single vaccines at specialist private clinics, the lack of the single mumps vaccine has caused much anxiety and controversy. It is estimated that between 400,000 and 500,000 children below the age of six are not immunised against mumps in the UK at present.

Fortunately the majority of these children are still at least five years away from puberty; 40% of adolescent boys who develop mumps during puberty will go on to suffer sterility problems so a British made vaccine will be popular.

It is concerning that over the last few years there have been a number of outbreaks of mumps across the UK; the most recent in February 2012 at Glasgow University where 37 students contracted the virus. With the introduction of a single mumps vaccine outbreaks of mumps should be reduced.

The Children?s Immunisation Centre has safely vaccinated 18,000 patients, many of them with weakened immune systems, with single vaccines over a ten year period, and has a 100% safety record with no cases of autism, febrile convulsions, hospitalisations or anaphylactic shock. Whilst the autism figure in the general population has grown and is now 1 in 80, many patients have chosen to vaccinate singly, leaving a gap of 4 ? 6 weeks between each vaccination.

More Puberty Press Releases